	US 12,303,559 B2
	Multivalent Epstein-Barr virus-like particles and uses thereof
Javier Gordon Ogembo, San Dimas, CA (US); Lorraine Zvichapera Mutsvunguma, Duarte, CA (US); and Felix Wussow, Duarte, CA (US)
Assigned to CITY OF HOPE, Duarte, CA (US)
Filed by CITY OF HOPE, Duarte, CA (US)
Filed on Mar. 21, 2024, as Appl. No. 18/612,771.
Application 18/612,771 is a continuation of application No. 16/647,705, granted, now 11,964,006, previously published as PCT/US2018/051268, filed on Sep. 16, 2018.
Claims priority of provisional application 62/559,528, filed on Sep. 16, 2017.
Prior Publication US 2024/0358813 A1, Oct. 31, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); C07K 16/00 (2006.01); C07K 16/08 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/12 (2013.01) [C07K 16/085 (2013.01); C12N 7/00 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55572 (2013.01); C07K 2317/76 (2013.01); C12N 2710/16222 (2013.01); C12N 2710/16223 (2013.01); C12N 2710/16234 (2013.01)]

20 Claims

1. An expression system for co-expressing a plurality of EBV envelope glycoproteins comprising an expression vector having two or more expression cassettes, wherein each of the two or more expression cassettes comprises:

a promoter,

a nucleic acid sequence encoding two or more EBV envelope glycoproteins, and

one or more linking sequences;

wherein the two or more EBV envelope glycoproteins are co-expressed simultaneously, self-cleaved and/or self-processed to assemble into one or more glycoprotein complexes.